Inflammation and Autoimmunity

T-Cell-Dependent Antibody Response (TDAR)

Biocytogen's TDAR assay, established using CD40/CD40L humanized mice, offers a robust in vivo model to evaluate T cell-dependent antibody responses. This platform enables detailed immunotoxicity and immunomodulation assessment for preclinical testing of biologics, vaccines, and other drug candidates.

on this page

  • T-cell Dependent Antibody Response (TDAR) Mouse Models
  • Keyhole limpet hemocyanin (KLH)-Induced TDAR Mouse Model
  • B-hCD40/hCD40L mice

Publication

    T-cell Dependent Antibody Response (TDAR) Assays
    T-cell dependent antibody response (TDAR) is a key immunological mechanism responsible for generating high-affinity, antigen-specific antibodies. This process plays a critical role in adaptive immunity and is fundamental to vaccine efficacy and protection against pathogens. TDAR assays, often induced using keyhole limpet hemocyanin (KLH), are widely used in preclinical studies to evaluate immune system function and immunotoxicity.
    In TDAR mouse models, such as those utilizing CD40/CD40L humanized mice, serum samples are collected at defined intervals to measure antigen-specific antibody levels via ELISA or other immunological assays. These assays offer crucial insights into the interplay between T and B cells, enabling the assessment of immune modulation, drug immunogenicity, and potential adverse effects of new therapeutic compounds.
    Keyhole Limpet Hemocyanin (KLH)-Induced TDAR Mouse Model
    Establishment of TDAR Mouse Model
    • Experimental Animals: B-hCD40/hCD40L mice , 7-8 weeks old, female
    • Modeling reagent: Keyhole Limpet Hemocyanin (KLH)
    • Modeling sites: Intraperitoneal injection (i.p.)
    • Modeling method: Intraperitoneal injection : day 0
    Readouts
    Optional tests Molecular levels Serum IgG and IgM
    Protein level (Elisa or Luminex)
    Efficacy Evaluation of Antibodies in TDAR Model of CD40/CD40L Humanized Mice (B-hCD40/hCD40L Mice)
    B-hCD40/hCD40L mice was used to establish the T-Dependent Antibody Response assay (TDAR assay) and evaluate the efficacy of anti-CD40 and anti-CD40L antibody. B-hCD40/hCD40L mice were used in a T-Dependent Antibody Response (TDAR) assay to evaluate anti-CD40 (bleselumab, in-house) and anti-CD40L (client-provided) antibody efficacy. Mice were intraperitoneally immunized with 100 μg KLH on Day 1. Blood was collected on Days 7 and 14 for ELISA analysis of KLH-specific IgG and IgM. (A) Body weight increased steadily. (B, C) KLH-specific IgG and IgM levels rose after immunization but were significantly reduced in anti-CD40L and bleselumab (anti-CD40)-treated groups, validating B-hCD40/hCD40L mice as a preclinical model for in vivo anti-CD40/CD40L antibody assessment. CD40 and CD40L antibodies suppress TDAR by blocking the essential CD40–CD40L co-stimulatory interaction required for T cell–dependent B cell activation and antibody production.